More on GKOS
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $176.69 |
|
|||
| Open | $175.95 | ||||
| 52 Wk High | $39.82 | ||||
| 52 Wk Low | $14.25 | ||||
| Day High | $179.70 | ||||
| Day Low | $173.08 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 961,235 | ||||
- Glaukos Corporation (GKOS) Reiterated at Buy by Stifel After Solid Q3 iDose Volume Diligence
- Glaukos iDose TR meets primary endpoint in Phase 4 cataract trial
- Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery
- Glaukos licenses retinal biologic RO-104 from RevOpsis Therapeutics
- Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases
- Form 4 GLAUKOS Corp For: Oct 05 Filed by: Navratil Tomas
- Glaukos reports three-year trial data for Epioxa keratoconus therapy
- Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus
- Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28
- Form 144 GLAUKOS Corp Filed by: Navratil Tomas
Entities mentioned with GKOS
- FDA | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- 13G | View Related Stories »
- Definitive Agreement | View Related Stories »
- Stifel | View Related Stories »
- Show More...
